AlphAIAlphAI — Financial news for AI agents
StockOTC · US · USDHealthcare · Biotechnology

$BETRF

BetterLife Pharma Inc.

Price · $BETRFvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $BETRF in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $BETRF in the last 30 days.

See all $BETRF insider activity →
Top stories · $BETRFMore →
SEP 17·finanznachrichten.deMed

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.

SEP 12·finanznachrichten.de

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.

AUG 31·newsfilecorp.com

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FSE: NPAU) appointed Charles Duncan, PhD, as Director and Chair of the Audit Committee. Dr. Duncan has 30 years of biotechnology and capital markets experience. The company granted him stock options for 500,000 shares, vesting over 24 months, and 125,000 shares, vesting over 3 months. BetterLife focuses on developing BETR-001 for migraine and headache disorders.

BETRF sentiment & insider activity

What's driving BETRF

  • BetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.

    finanznachrichten.de · Sep 17, 2026

  • BetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.

    finanznachrichten.de · Sep 12, 2026

  • BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FSE: NPAU) appointed Charles Duncan, PhD, as Director and Chair of the Audit Committee. Dr. Duncan has 30 years of biotechnology and capital markets experience. The company granted him stock options for 500,000 shares, vesting over 24 months, and 125,000 shares, vesting over 3 months. BetterLife focuses on developing BETR-001 for migraine and headache disorders.

    newsfilecorp.com · Aug 31, 2026

  • BetterLife Pharma Inc. (CSE: BETR) filed a preliminary prospectus for a public offering of common shares and pre-funded warrants. The biotech firm plans to use proceeds for clinical trials and working capital, with the offering expected to close by September 15, 2026, subject to regulatory approvals.

    finanznachrichten.de · Aug 25, 2026

AlphAI scores every news story that mentions BETRF with an AI model for sentiment and relevance, and aggregates insider trades from BetterLife Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BETRF

Score
SEP 17MedAI 8/10finanznachrichten.de

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.

4 min read
SEP 12HighAI 8/10finanznachrichten.de

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.

2 min read
AUG 31Lownewsfilecorp.com

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FSE: NPAU) appointed Charles Duncan, PhD, as Director and Chair of the Audit Committee. Dr. Duncan has 30 years of biotechnology and capital markets experience. The company granted him stock options for 500,000 shares, vesting over 24 months, and 125,000 shares, vesting over 3 months. BetterLife focuses on developing BETR-001 for migraine and headache disorders.

2 min read
AUG 25Medfinanznachrichten.de

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma Inc. (CSE: BETR) filed a preliminary prospectus for a public offering of common shares and pre-funded warrants. The biotech firm plans to use proceeds for clinical trials and working capital, with the offering expected to close by September 15, 2026, subject to regulatory approvals.

2 min read

Related tickers

More in Biotechnology